ADAM17 and metabolic dysfunction-associated steatohepatitis: Because NASH is a risk factor for HCC, a type of cancer increased in obesity33 we tested whether the protective effects of hepatocyte specific Timp3 overexpression and at a less extent of ADAM17 deletion will result in a slower tumor progression using a previously validated model34.